NCT05537220

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Feb 28, 2023
Primary completion: Mar 31, 2028
Completion date: Mar 31, 2028
First posted: Sep 13, 2022
Last posted: Sep 21, 2022
Enrollment: 438
Arms / groups: 2 / —
Source: AACT · ctgov ingestion

Sponsors

Johns Hopkins UniversityLead sponsor
Retina Foundation of the SouthwestCollaborator
National Eye Institute (NEI)Collaborator
University of PennsylvaniaCollaborator
Medical University of GrazCollaborator
University of LondonCollaborator
Harvard UniversityCollaborator
Duke UniversityCollaborator
Emory UniversityCollaborator
University of WashingtonCollaborator
Johns Hopkins UniversityStudy chair
Johns Hopkins UniversityStudy director
McGill UniversityCollaborator
Medical College of WisconsinCollaborator
Northwestern UniversityCollaborator
Radboud UniversityCollaborator
Stanford UniversityCollaborator
University of HoustonCollaborator
University of FloridaCollaborator
University of IowaCollaborator
University of MiamiCollaborator
University of MichiganCollaborator
University of OklahomaCollaborator
University of Southern CaliforniaCollaborator
Mayo ClinicCollaborator
University of California, DavisCollaborator
University of UtahCollaborator
Vanderbilt UniversityCollaborator
Vitreo-Retinal Associates, MichiganCollaborator
University of BaselCollaborator
University of MinnesotaCollaborator
University of AmsterdamCollaborator
University of WisconsinCollaborator
University of TuebingenCollaborator
Centro Medico ABCCollaborator

Drugs studied

acetylcysteine

Indications studied

Retinitis Pigmentosa

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.